R

Read Gene SA
WSE:RDG

Watchlist Manager
Read Gene SA
WSE:RDG
Watchlist
Price: 4.96 PLN -0.8% Market Closed
Market Cap: 58.5m PLN
Have any thoughts about
Read Gene SA?
Write Note

Relative Value

The Relative Value of one RDG stock under the Base Case scenario is 4.98 PLN. Compared to the current market price of 4.96 PLN, Read Gene SA is Fairly Valued.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RDG Relative Value
Base Case
4.98 PLN
Fairly Valued
Relative Value
Price
R
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
15
vs Industry
60
Median 3Y
4.9
Median 5Y
4.9
Industry
7.6
vs History
vs Industry
1
Median 3Y
-51.7
Median 5Y
-41.6
Industry
22.1
vs History
vs Industry
0
Median 3Y
29
Median 5Y
7.1
Industry
21.9
vs History
vs Industry
0
Median 3Y
-43.1
Median 5Y
-5.6
Industry
23.4
vs History
1
vs Industry
4
Median 3Y
8.9
Median 5Y
8.5
Industry
2.5
vs History
9
vs Industry
53
Median 3Y
4
Median 5Y
4
Industry
7.5
vs History
28
vs Industry
51
Median 3Y
4.8
Median 5Y
4.8
Industry
9.3
vs History
vs Industry
3
Median 3Y
31.3
Median 5Y
24.2
Industry
4.2
vs History
vs Industry
1
Median 3Y
-48.9
Median 5Y
-36.3
Industry
4
vs History
vs Industry
0
Median 3Y
20.7
Median 5Y
3.6
Industry
5.9
vs History
vs Industry
1
Median 3Y
20.7
Median 5Y
3.6
Industry
3.9
vs History
1
vs Industry
27
Median 3Y
4
Median 5Y
3.1
Industry
4.5

Multiples Across Competitors

RDG Competitors Multiples
Read Gene SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
PL
Read Gene SA
WSE:RDG
58.5m PLN 5 -58.3 -104.6 -55.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 142 781.8 -181 287 -220 140.1 -217 628.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 5.7 62 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 4.4 33.5 16.1 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 4.1 923.6 10.3 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD 9.8 -217.7 21.5 22.6
US
Epizyme Inc
F:EPE
94.1B EUR 1 847 -471.3 -513.2 -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 5.7 32.1 19.9 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 5.7 16.9 15.4 17.1
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.6 -52.9
NL
argenx SE
XBRU:ARGX
36B EUR 19.3 -135.2 -109.2 -79.6
P/S Multiple
Revenue Growth P/S to Growth
PL
R
Read Gene SA
WSE:RDG
Average P/S: 3 467 700.6
5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 142 781.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
20%
0.3
US
Amgen Inc
NASDAQ:AMGN
4.4
26%
0.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.1
10%
0.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
34%
0.3
US
E
Epizyme Inc
F:EPE
1 847
N/A N/A
AU
CSL Ltd
ASX:CSL
5.7
23%
0.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
23%
0.2
US
S
Seagen Inc
F:SGT
17.8
118%
0.2
NL
argenx SE
XBRU:ARGX
19.3
220%
0.1
P/E Multiple
Earnings Growth P/E to Growth
PL
R
Read Gene SA
WSE:RDG
Average P/E: 213.6
Negative Multiple: -58.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 287 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62
413%
0.2
US
Amgen Inc
NASDAQ:AMGN
33.5
73%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
923.6
77%
12
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -217.7
48%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -471.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.1
65%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.9
44%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -135.2 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
PL
R
Read Gene SA
WSE:RDG
Average EV/EBITDA: 16.4
Negative Multiple: -104.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -220 140.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
29%
0.5
US
Amgen Inc
NASDAQ:AMGN
16.1
62%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
16%
0.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.5
43%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -513.2 N/A N/A
AU
CSL Ltd
ASX:CSL
19.9
42%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
35%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.6 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -109.2 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
PL
R
Read Gene SA
WSE:RDG
Average EV/EBIT: 21.5
Negative Multiple: -55.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A

See Also

Discover More
Back to Top